Celcuity Inc 宣布,其候选药物Gedatolisib针对HR阳性、HER2阴性且PIK3CA基因为野生型的晚期乳腺癌患者所提交的新药申请,已获得美国食品药品监督管理局的正式受理。此次受理标志着该药物在审批流程中迈出了关键一步。
Celcuity Inc 宣布,其候选药物Gedatolisib针对HR阳性、HER2阴性且PIK3CA基因为野生型的晚期乳腺癌患者所提交的新药申请,已获得美国食品药品监督管理局的正式受理。此次受理标志着该药物在审批流程中迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.